USARx offers the following ways to purchase this medication. Choose the Best option for you!
Yes99% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$42 – $1040
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your creon prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about pancrelipase. Some of the dosage forms listed on this page may not apply to the brand name Creon.In Summary
More frequent side effects include: headache. See below for a comprehensive list of adverse effects.For the Consumer
Applies to pancrelipase: oral capsule delayed release, oral tablet
Along with its needed effects, pancrelipase (the active ingredient contained in Creon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking pancrelipase:
With high doses
With very high doses
With powder dosage form or powder from opened capsules- if breathed in
With tablets- if held in the mouth
Incidence not known
Some side effects of pancrelipase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to pancrelipase: oral capsule, oral capsule extended release, oral delayed release capsule, oral powder for reconstitution, oral tablet, oral tablet extended releaseGeneral
The most commonly reported side effects included gastrointestinal complaints, abdominal pain, and headaches.Gastrointestinal
Bowel stricture formation occasionally occurred in children with cystic fibrosis who received high doses.
Moderate duodenitis and gastritis occurred in a patient with exocrine pancreatic insufficiency due to cystic fibrosis 16 days after completing treatment with 4000 lipase units/gram fat ingested per day for 5 to 6 days, followed by placebo for an additional 5 to 6 days.
Very common (10% or more): Gastrointestinal complaints (up to 32%), abdominal pain (up to 18%)
Common (1% to 10%): Abdominal distention, abdominal pain upper, abnormal feces, anal pruritus, ascites, constipation, diarrhea, dyspepsia, early satiety, flatulence, frequent bowel movements, nausea, vomiting
Uncommon (0.1% to 1%): Abdominal discomfort, bowel stricture formation
Frequency not reported: Duodenitis, fibrosing colonopathy, gastritis, steatorrhea, strictures of the ileocecum
Postmarketing reports: Distal intestinal obstruction syndrome (DIOS)Nervous system
Very common (10% or more): Headache (up to 15%)
Common (1% to 10%): Dizziness
Postmarketing reports: Dull headache
A dull headache was reported by a patient receiving treatment with ursodeoxycholic acid concomitantly. The event resolved without sequelae after discontinuation of this drug.Metabolic
Common (1% to 10%): Decreased appetite, hyperglycemia, hypoglycemia, weight decreased
Frequency not reported: HyperuricemiaDermatologic
Common (1% to 10%): Rash, skin reactions
Frequency not reported: Pruritus/itching, urticaria/hives
Postmarketing reports: Blotchy/red facial rashHepatic
Common (1% to 10%): Biliary tract stones, hydrocholecystis
Postmarketing reports: Asymptomatic liver enzyme elevationsRespiratory
Common (1% to 10%): Cough, nasopharyngitis
Postmarketing reports: AsthmaCardiovascular
Common (1% to 10%): Contusion, peripheral edemaHematologic
Common (1% to 10%): Anemia
Frequency not reported: Transient neutropenia with/without clinical sequelaeRenal
Common (1% to 10%): Renal cystPsychiatric
Common (1% to 10%): IrritabilityImmunologic
Common (1% to 10%): Viral infectionHypersensitivity
A patient with a known history of allergy to another pancrelipase (the active ingredient contained in Creon) product developed a mild allergic reaction, including red, blotchy facial rash and itching. The event resolved without sequelae after discontinuation of this drug.
Frequency not reported: Anaphylactic reactions, hypersensitivity
Postmarketing reports: Anaphylaxis, mild allergic reactions, severe allergic reactionsOther
Frequency not reported: FatigueMusculoskeletal
Postmarketing reports: Muscle spasm, myalgiaOncologic
Postmarketing reports: Recurrence of preexisting carcinomaOcular
Postmarketing reports: Blurred vision
December 16, 2020
March 1, 2021
February 15, 2021
March 1, 2021
February 1, 2021
January 31, 2021